149 Results for "

CGA

" in MedChemExpress (MCE) Product Catalog:
Products (149)

149 Results for "CGA" in MCE Product Catalog:

86
86 Publications Verification
Cat. No.: HY-114180
CAS No.: 2262452-06-0
Purity:  99.95%
Synonyms: RU320521
Research Areas:  

Metabolic Disease

RU.521 (RU320521) is a potent and selective cyclic GMP-AMP synthase (cGAS) inhibitor and inhibits cGAS-mediated interferon upregulation. RU.521 suppresses dsDNA-activated reporter activity with an IC50 of 0.7 μM. RU.521 reduces constitutive expression of interferon in macrophages from a mouse model of Aicardi-Goutières syndrome (AGS) .
loading...
    loading...
34
34 Cited Publications
Cat. No.: HY-131454
CAS No.: 2375421-09-1
Purity:  99.89%
Target:  

STING

Research Areas:  

Inflammation/Immunology Cancer

SR-717 is a non-nucleotide STING agonist with EC50s of 2.1 μM and 2.2 μM in ISG-THP1 (WT) and ISG-THP1 cGAS KO (cGAS KO) cell lines, respectively. SR-717 is a stable cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) mimetic. Antitumor activity .
loading...
    loading...
34
34 Cited Publications
Cat. No.: HY-131454A
CAS No.: 2375420-34-9
Purity:  98.05%
Target:  

STING

Research Areas:  

Inflammation/Immunology Cancer

SR-717 free acid is a non-nucleotide STING agonist with EC50s of 2.1 μM and 2.2 μM in ISG-THP1 (WT) and ISG-THP1 cGAS KO (cGAS KO) cell lines, respectively. SR-717 free acid is a stable cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) mimetic. Antitumor activity .
loading...
    loading...
26
26 Cited Publications
Cat. No.: HY-13902
CAS No.: 1232416-25-9
Purity:  99.70%
Synonyms: VE-822; VX-970; M6620
Research Areas:  

Infection Metabolic Disease Cancer

Berzosertib (VE-822) is an orally active, CNS-penetrant, and selective ATR kinase inhibitor. Berzosertib blocks ATR kinase activity, abrogates G2/M cell cycle checkpoint, impairs DNA damage repair. Berzosertib induces apoptosis, inhibnits conlony migration, inhibits cell proliferation, and activates cGAS-STING axes in cancer cells. Berzosertib can be used for the research of cancers, such as head and neck squamous cell carcinoma, and colorectal cancer .
loading...
    loading...
26
26 Cited Publications
Cat. No.: HY-13902A
CAS No.: 1428935-04-9
Synonyms: VE-822 hydrochloride; VX-970 hydrochloride; M6620 hydrochloride
Research Areas:  

Neurological Disease Cancer

Berzosertib (VE-822) hydrochloride is an orally active, CNS-penetrant, and selective ATR kinase inhibitor. Berzosertib hydrochloride blocks ATR kinase activity, abrogates G2/M cell cycle checkpoint, impairs DNA damage repair. Berzosertib hydrochloride induces apoptosis, inhibnits conlony migration, inhibits cell proliferation, and activates cGAS-STING axes in cancer cells. Berzosertib hydrochloride can be used for the research of cancers, such as head and neck squamous cell carcinoma, and colorectal cancer .
loading...
    loading...
14
14 Cited Publications
Cat. No.: HY-15136
CAS No.: 193275-84-2
Purity:  99.60%
Synonyms: Sch66336
Lonafarnib (Sch66336) is an orally active, blood-brain barrier penetrant farnesyltransferase (FPTase) inhibitor. Lonafarnib increases the phosphorylation levels of Akt, CaMKII and CREB, upregulates BDNF expression in the hippocampus, elevates the content of α7nAChR on cell membranes, and blocks the isoprenylation of H-Ras. Lonafarnib repairs synapses and reverses spatial memory deficits in Aβ1-42 model mice. Lonafarnib inhibits RSV fusion and replication, and alleviates virus-induced lung injury. Lonafarnib activates the lysosomal and autophagic pathways, and reduces the phosphorylation and aggregation of tau. Lonafarnib acts synergistically with Sorafenib (HY-10201) to promote apoptosis, and inhibits the proliferation and invasion of melanoma cells. Lonafarnib inhibits the farnesylation of progerin, repairs nuclear membrane defects, and activates the cGAS-STING-STAT1 signaling pathway. Lonafarnib can be used in research related to diseases including Alzheimer's disease, viral infections, melanoma, and progeria .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-128583
CAS No.: 2369751-30-2
Purity:  99.12%
Research Areas:  

Inflammation/Immunology

G150 is a highly selective human cyclic GMP-AMP synthase (h-cGAS) inhibitor with an IC50 of 10.2 nM. G150 represses dsDNA-triggered interferon expression, and G150 can be used for the research of inflammatory .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-133916
CAS No.: 2369751-07-3
Purity:  99.17%
Research Areas:  

Inflammation/Immunology

G140 is a potent and selective inhibitor of cyclic GMP-AMP synthase (cGAS), with IC50s of 14.0 nM and 442 nM for h-cGAS and m-cGAS, respectively. G140 has anti-inflammatory activity .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-B0621
CAS No.: 68786-66-3
Synonyms: CGA89317
Research Areas:  

Infection

Triclabendazole is an orally active parasite inhibitor. Triclabendazole has anti-Leishmania activity and induces gasdermin E (GSDME)-dependent pyroptosis by caspase-3 activation. Triclabendazole can be used for the research of fasciola hepatica .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-150751
CAS No.: 1801724-76-4
Purity:  93.80%
Synonyms: ODN A151
ODN TTAGGG (ODN A151), an inhibitory oligonucleotide (ODN), is a TLR9, AIM2, and cGAS antagonist. ODN TTAGGG inhibits AIM2 inflammasome activation and cGAS activation through competition with DNA. ODN TTAGGG blocks AIM2-mediated Pyroptosis and inhibits IL-18 production. ODN TTAGGG has immunosuppressive effects and can be used in research on related autoimmune diseases such as lupus erythematosus . ODN TTAGGG sequence: 5'-T-T-A-G-G-G-T-T-A-G-G-G-T-T-A-G-G-G-T-T-A-G-G-G-3'.
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-150751C
Purity:  93.80%
Synonyms: ODN A151 sodium
Research Areas:  

Inflammation/Immunology

ODN TTAGGG sodium, inhibitory oligonucleotide (ODN), is a TLR9, AIM2 and cGAS antagonist. ODN TTAGGG sodium is immunosuppressive and inhibits AIM2 inflammasome activation, as well as cGAS activation, by competing with DNA. ODN TTAGGG sodium can be used in the study of lupus erythematosus and other related autoimmune diseases. ODN TTAGGG sequence: 5'-T-T-A-G-G-G-T-T-A-G-G-G-T-T-A-G-G-G-T-T-A-G-G-G-3' .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-160225
Research Areas:  

Inflammation/Immunology

ISD sodium is an interferon-stimulatory DNA, a 45 bp non-CpG double-stranded oligonucleotide derived from the genome of Listeria monocytogenes. ISD sodium potently induces type I interferon production via the cGAS‑STING‑TBK1‑IRF3 pathway .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-139056
CAS No.: 2210228-45-6
Purity:  99.96%
SU0268 is a potent and specific inhibitor of 8-Oxoguanine DNA glycosylase 1 (OGG1). SU0268 regulates inflammatory responses during Pseudomonas aeruginosa infection .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-114182
CAS No.: 2378173-15-8
Purity:  99.68%
Research Areas:  

Inflammation/Immunology

PF-06928215 is a cGAS (cyclic GMP-AMP Synthase) inhibitor with an IC50 of 4.9 μΜ. PF-06928215 has a high binding affinity of 0.2 μM (Kd) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-150724
CAS No.: 937402-51-2
Synonyms: 1018 ISS
Research Areas:  

Inflammation/Immunology

ODN 1018 (1018 ISS) is a TLR9 agonist and immune modulator. ODN 1018 exhibits adjuvant activity and augments CD8+ T cell responses with LNP-encapsulated OVA peptides. ODN 1018 triggers sustained suppression of allergic airway inflammation. ODN 1018 can be used for the research of allergic asthma and systemic lupus erythematosus .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-150741
CAS No.: 332437-00-0
Purity:  97.92%
ODN 2216 is a type A CpG oligodeoxynucleotide vaccine adjuvant and a TLR9 agonist. ODN 2216 interacts with TLR9 in the lysosomes of CD4 + T cells and activates feedback-dependent signaling pathways. ODN 2216 induces the production of type I interferons, IL-6 and TGF-β via the IRAK4/IRF7 axis, while increasing intracellular ATP levels. ODN 2216 not only induces the differentiation of CD4 + T cells into anti-inflammatory Th3-like regulatory phenotypes to inhibit autologous proliferation, but also enhances the specific CD8 + T cell-mediated cytotoxicity against Mammaglobin-A in breast cancer cells. ODN 2216 is widely used in studies related to breast cancer and systemic lupus erythematosus .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-B0821
CAS No.: 123312-89-0
Synonyms: CGA 215944
Research Areas:  

Infection

Pymetrozine is a feeding inhibitor of Homoptera, in preventing transmission of cauliflower mosaic caulimovirus by the aphid species Myzus persicae (Sulzer).
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N2616
CAS No.: 125-15-5
Vomicine modulates cGAS-STING-TBK1 signaling pathway, and exhibits anti-inflammatory activity. Vomicine is an alkaloid that can be isolated from Strychnos nux-vomica seeds .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-12464
CAS No.: 134605-64-4
Synonyms: WC-9717; CGA-276854
Target:  

Herbicide

Research Areas:  

Others

Butafenacil (WC-9717; CGA-276854) is an herbicide that inhibits protoporphyrinogen oxidase .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-124700
CAS No.: 1966129-74-7
LYPLAL1-IN-1 (compound 11) is a selective, covalent, and irreversible inhibitor of the lysophospholipase-like enzyme LYPLAL1 (IC50 = 6 nM). LYPLAL1-IN-1 shows selectivity against other serine hydrolases such as carboxylesterase CES1 (IC50 > 50 μM for CES1). LYPLAL1-IN-1 inhibits the depalmitoylation function of LYPLAL1, blocking its depalmitoylation modification of cyclic GMP-AMP synthase (cGAS), thereby promoting cGAS dimerization and activation, and initiating the cGAS-STING pathway-mediated innate immune response. LYPLAL1-IN-1 can enhance DNA-induced type I interferon production, upregulate PD-L1 expression in tumor cells, and promote the accumulation of tumor-infiltrating CD8 + T cells, with the core function of strengthening the anti-tumor immune response. LYPLAL1-IN-1 is primarily used in tumor immunology research, especially in combination with PD-1/PD-L1 inhibitors .
loading...
    loading...